MICOT PHARMA-B (02335) has been included in the Hang Seng Composite Index components.

MICOT PHARMA-B (02335) announced that, according to the quarterly review results of the Hang Seng Index series published by Hang Seng Indexes Company Limited on August 21, 2026, the company has been selected to be included as a constituent stock of the Hang Seng Composite Index (Hang Seng Composite Index), effective from September 7, 2026. Upon being included as a constituent stock of the Hang Seng Composite Index, the companys H shares are expected to qualify for inclusion in the Stock Connect program between Shanghai and Hong Kong, as well as Shenzhen and Hong Kong. The Stock Connect programs are channels for investors in Hong Kong and mainland China to trade and invest in stocks. The Board of Directors believes that inclusion in the Hang Seng Composite Index reflects the capital markets recognition of the company's value and growth potential, which will help broaden the companys shareholder base and enhance the trading liquidity of its H shares.